Skip to main content
Premium Trial:

Request an Annual Quote

Precision Antibody Completes SBIR Contract to Generate Antibodies for SISCAPA Assays


NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

Under the contract, Precision generated an unspecific number of new mouse monoclonal antibodies for use in SISCAPA mass spec assays.

SISCAPA uses antibody-based capture of target peptides prior to mass spec analysis to increase the sensitivity and throughput of traditional selected-reaction monitoring assays. As such, a catalogue of high-quality antibodies to peptide targets is key to the technology's utility.

Precision generated the antibodies using its proprietary Affinity Boost, SMART Fusion, and SeleKDt technologies, which, it said, enabled antibodies with higher affinity and lower off-rates than typical mouse monoclonals.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.